Turkish Journal of Nephrology
Case Report

The Use of Letermovir for Ganci clovi r-Res istan t Cytomegalovirus in Kidney Transplant Recipients

1.

Division of Nephrology, Clinical Hospital Center Zagreb, Zagreb, Croatia

2.

Department of Emergency Medicine, Clinical Hospital Dubrava, Zagreb, Croatia

Turkish J Nephrol 2022; 31: 257-260
DOI: 10.5152/turkjnephrol.2022.21226
Read: 114 Downloads: 68 Published: 01 July 2022

Resistant cytomegalovirus infection is a rising issue in kidney transplant recipients. Prolonged hospitalization, an increased burden for the patient, and worse outcomes are all potentiated by the use of highly toxic and poorly tolerated treatment options, which creates a growing need for investigation of safer alternatives. Letermovir represents a well-tolerated treatment option, and we present our experience in the treatment of 3 kidney transplant recipients with letermovir. Treatment outcomes were mixed; however, our results indicate the potential benefit of letermovir when used as step-down treatment and secondary prophylaxis.

Cite this article as: Bašić-Jukić N, Atić A . The use of letermovir for ganci clovi r-res istan t cytomegalovirus in kidney transplant recipients. Turk J Nephrol. 2022;31(3):257-260.

Files
EISSN 2667-4440